Generate Biomedicines, Inc. SEC filings GENB
Generate Biomedicines, Inc. has 56 filings in SEC EDGAR's recent list, going back to Dec 23, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 26, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 5, 2026 | — |
| 4 | Insider transaction | Nov 4, 2026 | Oct 29, 2026 |
| 144 | Notice of proposed sale | Oct 29, 2026 | — |
| 4 | Insider transaction | Sep 3, 2026 | Sep 1, 2026 |
| 144 | Notice of proposed sale | Sep 2, 2026 | — |
| 144 | Notice of proposed sale | Sep 1, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 26, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 3 | Initial insider ownership | Mar 12, 2026 | Mar 2, 2026 |
| 4 | Insider transaction | Mar 6, 2026 | Mar 4, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 4 | Insider transaction | Mar 2, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 2, 2026 | Feb 26, 2026 |
| S-8 | Employee stock plan registration | Feb 27, 2026 | — |
| 424B4 | Prospectus | Feb 27, 2026 | — |
| EFFECT | Filing | Feb 26, 2026 | — |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| 3 | Initial insider ownership | Feb 26, 2026 | Feb 26, 2026 |
| CERT | Filing | Feb 26, 2026 | — |
| 8-A12B | Filing | Feb 24, 2026 | — |
| S-1/A | Amended registration statement | Feb 23, 2026 | — |
| S-1/A | Amended registration statement | Feb 13, 2026 | — |
| S-1 | Registration statement | Feb 4, 2026 | — |
| DRS | Filing | Dec 23, 2025 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GENB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Somerville, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2100782
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.